Obsidian Therapeutics advances Agni-01 study with first patient enrolled in registration-enabling cohort

Summit Therapeutics expands ivonescimab programme into bladder cancer with Phase II/III trial

Lilly secures FDA Breakthrough Therapy designation for olomorasib in pancreatic cancer

Genprex collaborates with Roche Diagnostics on NSCLC biomarker validation

Zai Lab's zoci receives FDA orphan designation for neuroendocrine carcinomas

Qatar approves Zepzelca combination as first-line maintenance therapy for extensive-stage small cell lung cancer

Datroway approved in EU for first-line metastatic triple-negative breast cancer

10x Genomics and Lausanne University Hospital to collaborate on cancer care research

BeOne Medicines expands US manufacturing with USD300m investment

GSK's Jideytro (zidesamtinib) gains US approval for previously treated ROS1-positive NSCLC

Kelun-Biotech's Phase III study of sac-TMT in combination with pembrolizumab meets primary endpoint

AstraZeneca signs global licence deal with Dizal for lung cancer drug Zegfrovy

Insilico initiates Rentosertib Phase III clinical trial for idiopathic pulmonary fibrosis

Genentech reports positive Phase III results for divarasib in KRAS G12C lung cancer

Abbisko Therapeutics and AstraZeneca collaborate to conduct combination clinical trial for NSCLC